ABOS

Acumen Pharmaceuticals, Inc. ABOS

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-25.37M

Quarter to Sep 30

Free cash flow

$-26.65M

Quarter to Sep 30

Top Institutional Holders

as of Q2 2026
$127.78M total
RA CAPITAL MANAGEMENT, L.P.
$56.05M0.0%
Sands Capital Ventures, LLC
$9.93M0.0%
BlackRock, Inc.
$6.65M+1296.4%
Alyeska Investment Group, L.P.
$6.55M0.0%
FRANKLIN RESOURCES INC
$6.15M0.0%
ADAR1 Capital Management, LLC
$5.64M-2.1%
VANGUARD CAPITAL MANAGEMENT LLC
$4.46M+11.0%
Knollwood Investment Advisory, LLC
$4.35M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$3.05M+174.3%
Ikarian Capital, LLC
$2.81M0.0%
Hudson Bay Capital Management LP
$2.55M-1.4%
Pathstone Holdings, LLC
$2.29M0.0%
RENAISSANCE TECHNOLOGIES LLC
$1.80M+42.4%
TWO SIGMA INVESTMENTS, LP
$1.66M+17.3%
STATE STREET CORP
$1.60M+295.8%
NORTHERN TRUST CORP
$963.2K+379.6%
VANGUARD PORTFOLIO MANAGEMENT LLC
$856.5KNew
DIMENSIONAL FUND ADVISORS LP
$779.0K+143.5%
VANGUARD FIDUCIARY TRUST CO
$777.6K+46.2%
BANK OF AMERICA CORP /DE/
$733.7K-14.2%
BOOTHBAY FUND MANAGEMENT, LLC
$728.9K0.0%
ACADIAN ASSET MANAGEMENT LLC
$718.0K+45.5%
NOMURA HOLDINGS INC
$506.5KNew
GOLDMAN SACHS GROUP INC
$491.1K-11.0%
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$470.4K0.0%
See all 96 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q3 2026
EDGAR

EPS (Diluted)

Q3 2026
EDGAR

Free Cash Flow

Q3 2026
EDGAR

Debt/Equity

Q3 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ABOS

Earnings Per Share

13fpro.ai/company/ABOS

Loading ratio trend…

ABOS key financials by period

Reported revenue, net income and operating margin by fiscal year, from Acumen Pharmaceuticals, Inc.'s annual filings on SEC EDGAR.

Acumen Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$10.2M$-52.4M—
FY 2022$2.4M$-42.9M—
Source: ABOS filings on SEC EDGAR →

ABOS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Acumen Pharmaceuticals, Inc. (ABOS): stock profile, AI score and financials

Acumen Pharmaceuticals, Inc. (ABOS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ABOS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q3 2026), Acumen Pharmaceuticals, Inc. reports net income of $-25.4M, free cash flow of $-26.7M. Top institutional holders of ABOS by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., Sands Capital Ventures, BlackRock, based on the most recent SEC filings. ABOS trades on the Nasdaq exchange and files with the SEC under CIK 1576885. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABOS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Acumen Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1576885 →